pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rybrevant · news · pharmadog
← back to Rybrevant
News mentioning Rybrevant
12
stories
17d
Rare EGFR mutation increases lung cancer risk 62 times in never smokers
fiercebiotech
19d
Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
biospace
23d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
Aug 13, 26
New Taiho, Cullinan data heats up lung cancer drug battle
biopharma dive
Aug 13, 26
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
biospace
Aug 13, 26
Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
endpoints
Aug 13, 26
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
fiercebiotech
Aug 7, 26
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
Aug 3, 26
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 17, 26
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech
May 7, 26
EGFR-Targeted Therapy Sequencing After Resistance in NSCLC
onclive
